By the Metrics Surgical Oophorectomy Plus Tamoxifen is the First Adjuvant Treatment Option for Premenopausal Women with Hormone Receptor Positive Breast Cancer

“The right measure for successful health care isn’t about the maximum possible for a few, but theaverage for everyone… and the minimumopportunities available to even those with the fewestresources and privileges”.“How you define the problem determineswhether you solve it.”Outcomes for the majority of women with breastcancer, most of whom, but hardly all, do not live inhigh-income countries, are poor.3 The breast cancersub-group of premenopausal women with hormonepositive tumors is large: at a minimum: 550,000 totalnew cases/year, 420,000 of whom come from lowandmiddle-income countries (LMICs), with 82% ofthe global population. Based on Globocan estimatesfor all new breast cancer cases for 2018 at 2.088million, this subgroup number may be as high as700,000 cases.

By the Metrics Surgical Oophorectomy Plus Tamoxifen is the First Adjuvant Treatment Option for Premenopausal Women with Hormone Receptor Positive Breast Cancer Keywords:

Premenopausal Women